The stock of Wave Life Sciences Ltd (NASDAQ:WVE) is a huge mover today! The stock decreased 4.00% or $1.3 during the last trading session, hitting $31.17. About 66,378 shares traded hands. Wave Life Sciences Ltd (NASDAQ:WVE) has risen 121.06% since March 1, 2016 and is uptrending. It has outperformed by 108.85% the S&P500.
The move comes after 9 months negative chart setup for the $737.45 million company. It was reported on Oct, 4 by Barchart.com. We have $28.99 PT which if reached, will make NASDAQ:WVE worth $51.62 million less.
Analysts await Wave Life Sciences Ltd (NASDAQ:WVE) to report earnings on December, 15. They expect $-0.40 earnings per share, up 25.93% or $0.14 from last year’s $-0.54 per share. After $-0.51 actual earnings per share reported by Wave Life Sciences Ltd for the previous quarter, Wall Street now forecasts -21.57% EPS growth.
Wave Life Sciences Ltd (NASDAQ:WVE) Ratings Coverage
Out of 5 analysts covering WAVE Life Sciences (NASDAQ:WVE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. WAVE Life Sciences has been the topic of 5 analyst reports since December 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Suntrust Robinson with “Buy” on Monday, December 7. The rating was initiated by Leerink Swann on Monday, December 7 with “Outperform”. The firm has “Buy” rating given on Monday, December 7 by Jefferies. SunTrust initiated the stock with “Buy” rating in Monday, December 7 report. The stock of Wave Life Sciences Ltd (NASDAQ:WVE) has “Mkt Outperform” rating given on Monday, December 7 by JMP Securities.
According to Zacks Investment Research, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.”
More notable recent Wave Life Sciences Ltd (NASDAQ:WVE) news were published by: Marketwatch.com which released: “WAVE Life Sciences Ltd.” on November 11, 2015, also Businesswire.com with their article: “WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically …” published on May 05, 2016, Businesswire.com published: “WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018” on January 29, 2016. More interesting news about Wave Life Sciences Ltd (NASDAQ:WVE) were released by: Businesswire.com and their article: “WAVE Life Sciences to Present at the SunTrust Robinson Humphrey 2016 Orphan …” published on February 16, 2016 as well as Businesswire.com‘s news article titled: “WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides …” with publication date: May 16, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.